Molecular-targeted agents, including vascular epidermal growth factor (VEGF) inhibitors, fibroblast growth factor (FGF) inhibitors, and isocitrate dehydrogenase (IDH) inhibitors, have provided new ideas for further treatment in advanced ICC (9, 17, 18). The gene discussed is IDH3A; the disease is intrahepatic cholangiocarcinoma.